Key idiopathic inflammatory myositis companies, including Octapharma, Pfizer, Mitsubishi Tanabe Pharma, AstraZeneca, Priovant Therapeutics, and CSL, among others, are advancing the treatment landscape with promising therapies, addressing the substantial unmet needs in this rare autoimmune disorder. DelveInsight's " Idiopathic Inflammatory Myositis Market Insight, Epidemiology and Market Forecast - 2034 " report delivers comprehensive insights into idiopathic inflammatory myositis, including historical and forecasted epidemiology, current treatment paradigms, and emerging therapies across the United States, EU4, the UK, and Japan. The idiopathic inflammatory myositis market size in the 7MM, valued at approximately USD 450 million in 2023, is projected to grow substantially at an impressive CAGR of 21.1% during the forecast period (2024-2034). Furthermore, the US accounts for approximately USD 270 million of the total market share in 7MM in 2023, followed by EU4 and the UK with approximately USD 160 million.